Clinical trials: Glomerulonephritis, Membranous
Focal Segmental Glomerulosclerosis, Minimal Change Disease
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN).
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Trial name
- NCT06664814
- Testing
- ManNAc
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Nephrotic Syndrome, Proteinuria
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Background: Membranous nephropathy is associated with damage to the walls of the glomeruli, the small blood vessels in the kidneys that filter waste products from the blood.
- Conditions
- Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease
- Trial name
- NCT00977977
- Testing
- Rituximab Infusion, Oral Cyclosporine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Membranous Nephropathy
Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis
To assess the correlation of these urinary biomarkers with the serum sample and evaluated the clinical utility of using urinary sample in the detection and prognostication of MGN.
- Trial name
- NCT05688865
- Testing
- urinary markers
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- Chinese University of Hong Kong
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
Membranous Nephropathy
Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy
High-grade proteinuria is one of the key determinants of adverse renal prognosis in patients with primary membranous nephropathy (PMN).The main purpose of this study is to determine whether Rituximab combined with Cyclosporine is…
- Trial name
- NCT07861204
- Testing
- Rituximab combined with cyclosporine, rituximab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University First Hospital
Membranous Nephropathy
Obinutuzumab in Primary MN
Primary membranous nephropathy (MN) is an antibody-mediated autoimmune glomerular disease, that represents one of the most frequent causes of nephrotic syndrome in adults.
- Trial name
- ORION (NCT05050214)
- Testing
- Obinutuzumab
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Glomerulonephritis, Membranous
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
- Trial name
- MOMENT (NCT07851220)
- Testing
- Inebilizumab, Tacrolimus
- Where
- 4 sites in United States
- Volunteers
- 159 people
- Sponsor
- Amgen
Membranous Nephropathy, Nephrotic Syndrome
Belimumab With Rituximab for Primary Membranous Nephropathy
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with…
- Trial name
- REBOOT (NCT03949855)
- Testing
- Belimumab, Rituximab
- Where
- 20 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Diseases, Chronic, Glomerular Diseases
Model Development and Application Based on Renal Pathology Images
This single-center retrospective observational cohort study will utilize digital renal pathology images along with corresponding clinical and laboratory data from patients who underwent kidney biopsy at Union Hospital, Tongji…
- Conditions
- Kidney Diseases, Chronic, Glomerular Diseases, Tubulointerstitial Kidney Diseases, IgA Nephropathy (IgAN)
- Trial name
- NCT07816874
- Where
- China
- Volunteers
- 8,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
IgA Nephropathy (IgAN), Membranous Nephropathy
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
This study is a single-arm, open-label, dose-escalation and dose-expansion clinical trial, divided into two phases: the first phase is the dose-escalation phase, and the second phase is the dose-expansion phase.
- Conditions
- IgA Nephropathy (IgAN), Membranous Nephropathy, ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN), Refractory Podocytopathy
- Trial name
- NCT07389499
- Testing
- CD19-targeted iNKT Cell Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Grit Biotechnology
Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced
Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab
Membranous nephropathy is a rare autoimmune kidney disease in which autoantibodies, most commonly anti-PLA2R1 antibodies, target podocyte antigens and may cause nephrotic syndrome.
- Conditions
- Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Nephrotic Syndrome
- Trial name
- TRANSCRIPT (NCT07811557)
- Testing
- Peripheral blood immune-cell profiling by single-cell RNA sequencing and in vitro pathway modulation assays
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Membranous Nephropathy, Nephrotic Syndrome
Clinical Prediction Model for Disease Progression in Primary Membranous Nephropathy
This prospective observational study aims to evaluate predictors of disease progression in patients with primary membranous nephropathy and to assess the performance of a prognostic nomogram in predicting renal outcomes in the…
- Conditions
- Membranous Nephropathy, Nephrotic Syndrome, Kidney Diseases
- Trial name
- NCT07785739
- Volunteers
- 128 people
- Sponsor
- Assiut University
Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome
To confirm the efficacy and safety of rituximab (genetical recombination) intravenously administered to idiopathic membranous nephropathy with nephrotic syndrome.
- Trial name
- PRIME (NCT05914155)
- Testing
- Rituximab (genetical recombination)
- Where
- 18 sites in Japan
- Volunteers
- 88 people
- Sponsor
- Shoichi Maruyama MD PhD
IgA Nephropathy (IgAN), Primary Membranous Nephropathy
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
This is an investigator initiated, single-arm, open-label, dose-escalation study to explore the preliminary efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the universal STAR-T…
- Trial name
- NCT07746453
- Testing
- Universal STAR-T Cell
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Guangdong Provincial People's Hospital
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and…
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
- Trial name
- NCT06466135
- Testing
- WAL0921
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 96 people
- Sponsor
- Walden Biosciences
IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
QLS7305 injection is a chemically synthesized double-stranded small interfering RNA (siRNA) targeting complement C3, covalently linked to a ligand containing N-acetylgalactosamine (GalNAc) residues.
- Conditions
- IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G), Primary Membranous Nephropathy
- Trial name
- NCT07730632
- Testing
- QLS7305 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lupus Nephritis, Membranous Nephropathy
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
Lupus nephritis (LN) is a frequent and severe complication of systemic lupus erythematosus, with important mortality and morbidity.
- Trial name
- OBLUMEN (NCT07721363)
- Testing
- Obinutuzumab
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Membranous Nephropathy, Minimal Change Disease (MCD)
Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome
Immunophenotyping profiling of patients with primary MN, primary FSGS and MCD. Evaluation of these immune cell subsets as possible biomarkers to track response to treatment or disease relapse.
- Conditions
- Membranous Nephropathy, Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT07702981
- Testing
- Rituximab (MABTHERA® or RITUXAN®)., Corticosteroids (CS)
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ioannina
Membranous Nephropathy
MOR202 for Refractory MN
Membranous nephropathy (MN) - the leading cause of nephrotic syndrome (NS) in adults - is an immune-mediated disease that results from the deposition of immunoglobulins and complement components onto the sub-epithelial layer of…
- Trial name
- MONET (NCT04893096)
- Testing
- MOR202
- Where
- 2 sites in Italy
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research